首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1630766

大環內酯類抗生素市場規模、佔有率和成長分析（按藥物、管理、適應症、最終用戶和地區）- 產業預測 2025-2032

Macrolide Antibiotics Market Size, Share, Growth Analysis, By Drugs (Azithromycin, Clarithromycin), By Administration (Oral, Parenteral), By Indication, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月09日 | 出版商:

SkyQuest | 英文 218 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球大環內酯類抗生素市場規模價值 58 億美元，預計將從 2024 年的 59.3 億美元成長到 2032 年的 71.2 億美元，預測期內（2025-2032 年）的複合年成長率為 2.3%。

隨著全球感染疾病發生率的上升，大環內酯類抗生素市場預計將出現成長。大環內酯類抗生素的特徵是具有大環內酯結構，能與細菌核醣體結合並抑制蛋白質合成，對多種感染疾病有效，包括性行為感染和肺炎、支氣管炎等呼吸道疾病。根據美國生物技術資訊中心的數據，肺炎的發生率相當高，全球每 1,000 人中有 1.5 至 14 例，美國每 10,000 人中有 24.8 例，尤其是老年人。學名藥的普及進一步推動了對這些抗生素的需求不斷成長，各公司都在努力開發與原始大環內酯類學名藥，以增加其在市場上的佔有率。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分析市場佔有率
- 收益與前一年同期比較（2022-2024 年）

主要企業簡介

Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
AbbVie Inc.（USA）
Sanofi SA（France）
Novartis AG（Switzerland）
GlaxoSmithKline plc（UK）
Teva Pharmaceutical Industries Ltd.（Israel）
Mylan NV（USA）
Daiichi Sankyo Company, Limited（Japan）
Sun Pharmaceutical Industries Limited（India）
Cipla Limited（India）
Lupin Limited（India）
Zydus Lifesciences Limited（India）
Alkem Laboratories Ltd.（India）
Zhejiang Guobang Pharmaceutical Co., Ltd.（China）
Bristol Myers Squibb（USA）
Abbott Laboratories（USA）
Eli Lilly and Company（USA）
Amgen Inc.（USA）
Sandoz International GmbH（Germany）

結論和建議

簡介目錄

Product Code: SQMIG35I2327

Global Macrolide Antibiotics Market size was valued at USD 5.8 billion in 2023 and is poised to grow from USD 5.93 billion in 2024 to USD 7.12 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The macrolide antibiotic market is poised for growth, driven by a rising global prevalence of infectious diseases. Macrolides, characterized by their macrocyclic lactone structure and ability to inhibit protein synthesis by binding to the bacterial ribosome, are effective against various infections, including sexually transmitted diseases and respiratory ailments like pneumonia and bronchitis. The National Centre for Biotechnology Information reports significant rates of pneumonia, with incidences ranging from 1.5 to 14 cases per 1,000 people globally, and 24.8 cases per 10,000 in the United States, especially among older adults. The increasing demand for these antibiotics is further bolstered by the availability of generic options, as companies strive to develop equivalents to branded macrolides, enhancing their market presence.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macrolide Antibiotics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macrolide Antibiotics Market Segmental Analysis

Global Macrolide Antibiotics Market is segmented by Drugs, Administration, Indication, End User and region. Based on Drugs, the market is segmented into Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin. Based on Administration, the market is segmented into Oral and Parenteral. Based on Indication, the market is segmented into Infection due to mycoplasma pneumonia, Legionella sp,or Bordetella pertussis, Symptomatic cat-scratch disease, Bacillary angiomatosis, Peliosis hepatis in patients with AIDS, Cebebral taxoplasmosis, Uncomplicated skin infection and Others. Based on End User, the market is segmented into Hospitals, Dermatology clinics, Pharmaceutical companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macrolide Antibiotics Market

The global macrolide antibiotics market is experiencing significant growth driven by emerging trends in developing nations such as China, India, and Brazil. These markets present substantial opportunities due to their large populations and increasing healthcare expenditures, which contribute to a rising demand for antibiotics. As bacterial infections become more prevalent in these regions, the need for effective treatment solutions continues to escalate. Consequently, manufacturers of macrolide antibiotics can expand their market presence and capitalize on the growing demand for innovative and efficient alternatives. This combination of factors positions the macrolide antibiotics market for remarkable expansion in the coming years.

Restraints in the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market faces significant constraints due to the increasing prevalence of antibiotic-resistant microorganisms, particularly to macrolides. This resistance primarily arises from the overuse and misuse of antibiotics, posing a critical challenge to the long-term viability of macrolide treatments for bacterial infections. As the effectiveness of these drugs diminishes, the market potential for macrolide antibiotics is compromised. Addressing the escalating issue of antibiotic resistance necessitates the development of new pharmacological options and alternative therapeutic strategies to ensure effective treatment and mitigate the impact of resistant bacteria on public health.

Market Trends of the Global Macrolide Antibiotics Market

The Global Macrolide Antibiotics market is increasingly shaped by the urgent need to address bacterial resistance and enhance treatment efficacy. Pharmaceutical companies are innovating to develop new macrolide derivatives and advanced formulations, focusing on improving pharmacokinetics and expanding their spectrum of activity. This trend reflects a commitment to counteract evolving microbial threats while optimizing existing macrolide treatments for a wide range of bacterial infections. Additionally, increasing awareness of antibiotic resistance is driving research investments, suggesting a dynamic market landscape poised for growth. Consequently, the macrolide antibiotic sector is adapting to meet the pressing challenges posed by resistant pathogens in the healthcare environment.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Macrolide Antibiotics Market Size by Drugs & CAGR (2025-2032)

Market Overview
Azithromycin
Clarithromycin
Erythromycin
Fidaxomicin
Telithromycin

Global Macrolide Antibiotics Market Size by Administration & CAGR (2025-2032)

Market Overview
Oral
Parenteral

Global Macrolide Antibiotics Market Size by Indication & CAGR (2025-2032)

Market Overview
Infection due to mycoplasma pneumonia
Legionella sp,or Bordetella pertussis
Symptomatic cat-scratch disease
Bacillary angiomatosis
Peliosis hepatis in patients with AIDS
Cebebral taxoplasmosis
Uncomplicated skin infection
Others

Global Macrolide Antibiotics Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Dermatology clinics
Pharmaceutical companies
Others

Global Macrolide Antibiotics Market Size & CAGR (2025-2032)

North America (Drugs, Administration, Indication, End User)
- US
- Canada
Europe (Drugs, Administration, Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drugs, Administration, Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drugs, Administration, Indication, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Drugs, Administration, Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Lifesciences Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alkem Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments